All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Hydrocortisone
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Eton Pharmaceuticals
Deal Size: $7.5 million Upfront Cash: $3.5 million
Deal Type: Licensing Agreement March 27, 2020
Details:
The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.